Endo Health Solutions, a Malvern, Penn.-based diversified healthcare company, has named Rajiv De Silva as president and CEO, effective March 18. De Silva, who will also join the Endo board of directors, succeeds David Holveck, who is retiring.

De Silva brings deep experience in the pharmaceutical sector. He most recently served as president of Valeant Pharmaceuticals, a $20 billion market capitalization specialty pharmaceutical company with a presence in the U.S. and a wide range of international markets.  While at Valeant from 2009 to 2013, De Silva also served as chief operating officer of Valeant's specialty pharmaceuticals business. Prior to joining Valeant, he served as a senior executive at Novartis from 2003 to 2008, most recently serving as president of its vaccines business in the U.S. and the head of vaccines in the Americas. De Silva also served as president and CEO of Novartis Pharmaceuticals Canada and global head of strategic planning for Novartis Pharma. Earlier in his career, he was a principal at McKinsey & Company, where he served as a member of the partnership group that led the global Pharmaceutical and Medical Products practice.

De Silva currently serves on the board of AMAG Pharmaceuticals, a publicly traded specialty pharmaceutical company focused on nephrology, hematology, and oncology.